Littleton, CO, April 28, 2011 --(PR.com
)-- Novus Biologicals announced today a new USP22 antibody (catalog number NBP1-49644) for the study of ubiquitin-dependent metabolic pathways. This USP 22 antibody was made using SDIX's Genomic Antibody TechnologyTM (GATTM).
Deubiquitinating enzymes (DUBs) comprise a large group of proteases that cleave ubiquitin from proteins to regulate ubiquitin-dependent metabolic pathways. DUB proteins are responsible for ubiquitin recycling, ubiquitin precursor processing, protein ubiquitination proofreading, and inhibitory ubiquitin chain disassembly. Also known as deubiquitinating peptidases, deubiquitinating isopeptidases, deubiquitinases, ubiquitin proteases, ubiquitin hydrolyases or ubiquitin isopeptidases, DUBs can act as both positive and negative regulators of the ubiquitin system. Please visit their website for a complete list of all their ubiquitin proteasome pathway related products.
Ubiquitin carboxyl-terminal hydrolase 22 (USP-22) is the DUB component of the transcription regulatory histone acetylation complex SAGA, which coactivates histones H2A and H2B by catalyzing their deubiquitination. Novus has recently released a new USP22 Antibody (NBP1-49644) for use in WB on human and mouse samples. USP-22 is also thought to be required for transcription, nuclear receptor-mediated transactivation and cell cycle progression, so the USP22 antibodies will serve as important tools for new research in a diverse set of areas.
GAT uses sophisticated bioinformatics and immunization strategies to produce high-quality antibodies that specifically bind to that region of the protein in its naturally folded form. The ability of any antibody to recognize a protein’s naturally folded state has the potential to expand an antibody’s utility to high-value applications like sandwich immunoassay, ChIP, and flow cytometry. Learn more about GAT by reading the GAT FAQ or by downloading the GAT White Paper.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.
About SDIX (www.sdix.com )
SDIX is a biotechnology company, expert at creating advantage by providing a broad range of quality, innovative and effective immuno-solutions to the pharmaceutical, biotechnology, diagnostics, and food safety markets. For 20 years, SDIX has developed antibodies which advance its customers’ immuno-based work – reducing time, labor, and costs while increasing accuracy and reliability of results.
SDIX offers a full suite of integrated immuno-solution capabilities including assay design, development, and production. In life science markets, SDIX capabilities are being used to help discover the mechanisms of disease, facilitate the development of new drugs, and provide tools for rapid diagnosis.
This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.